Navigation Links
Evotec Reports Positive Proof-of-Concept Top-Line Results with,Insomnia Drug Candidate EVT 201

ected to be announced by Q4 2007 / Q1 2008.

Study design

This US, multi-centre, double-blind trial was designed to evaluate the efficacy of EVT 201 in a three way cross-over design in 67 patients with primary insomnia. Patients were screened for entry into the study and the eligibility criteria included: a diagnosis of primary insomnia according to DSM (Diagnostic and Statistical Manual of Mental Disorders) IV; mean LPS > 20 minutes, mean WASO �³ 40 minutes, mean TST 240-420 minutes, all determined during two consecutive nights PSG evaluation. Patients received two dose levels of EVT 201 and placebo, in a random order, for two consecutive nights with a 5-12 day washout between each period.

The primary endpoints of this trial were to assess Wake After Sleep Onset (WASO) as well as Total Sleep Time (TST) determined by polysomnography (PSG). The secondary endpoints included additional PSG-based measures such as latency to persistent sleep, number of awakenings and effects on sleep architecture. In addition, patients evaluated sleep quality and quantity. Residual sedation was assessed by the Digit Symbol Substitution Test (DSST) and a categorical patient rating. Safety measures included adverse events and laboratory data.

Conference call

Evotec will hold a conference call today at 4.00 pm CET (3.00 pm GMT/10.00 am US time East Coast) to discuss the top-line results.

    Conference call numbers (listen only):


    Europe: +49-(0)69-5007-1309 (Germany)

            +44-(0)20-7806-1955 (UK)


    US: +1-718-354-1388



    Webcast: www.evotec.com

    The presentation slides are available via the webcast.

A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49-(0)69-22222-0418 (Germany) or +44-(0)20-7806-1970 (UK) and in the US by +1-718-354-1112. The access code is 1624428#. The on-demand vers
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
(Date:7/31/2014)... 31, 2014  Decision Resources Group,s experts ... by the Affordable Care Act (ACA), which ... pharmaceutical therapies. The ACA altered how Managed ... regulations and expanded access via government-supported programs. ... exchanges—state-based marketplaces set up by states or ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... Untold Numbers of Consumers Still Left Disabled By Its ... GlaxoSmithKline, the maker of popular denture adhesives Poligrip and Super ... its denture adhesive products.  The pharmaceutical giant has added the potentially ... consuming large quantities of zinc over an extended period of time ...
... , , SHANGHAI , ... WX ), a leading pharmaceutical, biotechnology and medical device R&D outsourcing ... announced that it will release financial results for the fourth quarter of ... 8, 2010 (which will be Tuesday morning, March 9, 2010 ...
Cached Medicine Technology:Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 2Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 3WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 2WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 3
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... in regulating appetite and whole-body metabolism. A protein known ... food intake and body weight, but the identity of ... A new study in the Journal of ... type of neuron known as pro-opiomelanocortin (POMC) neurons is ... Sabrina Diano and colleagues at Yale University School of ...
(Date:8/1/2014)... Barbara Bronson Gray HealthDay Reporter ... obese and work in manufacturing jobs may have significantly less endurance ... a study of 32 people -- half were obese, half were ... times that were about 60 percent longer. Obesity also was ... Being older -- 50 to 65 years of ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- The U.S. Food and ... new drug, Jardiance, to help fight type 2 diabetes. ... added to existing treatment regimens to control blood sugar ... Rosebraugh, director of the Office of Drug Evaluation II ... said in an agency statement. The FDA also ...
(Date:8/1/2014)... study, researchers at University Hospitals Rainbow Babies & Children,s ... at greater risk for death on a commercial airline ... worldwide between January 2010 and June 2013 and found ... age of 2. , The study was conducted ... of an in-flight pediatric fatality onboard commercial airline flights ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:New research characterizes in-flight pediatric deaths 2
... and areas for improvement in reform proposals for small businesses ... on Small Business and Entrepreneurship Chair Mary Landrieu, D-La., and ... to better understand the needs of small businesses in health ... those needs. , "We are here today to discuss one ...
... , WASHINGTON, Oct. 20 Speaker Nancy Pelosi, House ... Michigan held a press availability this afternoon ... the urgency of health insurance reform for children with pre-existing ... and Jessica Segal of Texas told ...
... benefits patients, study shows , TUESDAY, Oct. 20 (HealthDay ... patients when used up to 4.5 hours after a ... provide further evidence to increase the tPA treatment window ... Previously published findings from the ECASS III study indicated ...
... 20 (HealthDay News) -- In an effort to reduce ... Reproductive Medicine has revised its recommendations on the number ... fertilization procedures. , The society reports that the ... For one, it says that doctors should only use ...
... Body Worlds 2 & The Brain ... October 17, and will be one of many points of ... of scientific treasures. The second-largest medical research and education center ... medical, anatomical and scientific sites--from the nation,s first hospital and ...
... patients in U.S. hospitals fail to get recommended therapy, ... A recommended treatment for heart failure is underused in ... of aldosterone antagonist therapy in patients with heart failure ... failure guidelines established by the American College of ...
Cached Medicine News:Health News:Landrieu, Snowe Champion Small Business Health Care Reform Efforts 2Health News:Pelosi Remarks at Press Availability with Easter Seals on Benefits of Health Reform for Children 2Health News:Pelosi Remarks at Press Availability with Easter Seals on Benefits of Health Reform for Children 3Health News:Stroke Treatment Window May Allow a Bit More Time 2Health News:New IVF Guidelines Aim to Reduce Multiple Births 2Health News:Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond 2Health News:Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond 3Health News:Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond 4Health News:Heart Failure Treatment Underused 2
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Peribulbar Needle, 25 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Scleral Blade tip 5700 style, straight. Dimensions: 15.2 mm (L) x 3.4 mm (W). Cut: 2.7 mm....
Blade tip handle....
Medicine Products: